An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-NW-3509 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2018
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Newron Pharmaceuticals
- 11 Apr 2018 Status changed from not yet recruiting to recruiting.
- 02 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.
- 28 Feb 2018 New trial record